Quality Assurance Policy

Taj Pharmaceuticals Redefining Pharmaceutical Manufacturing
Pharmaceutical Manufacturing

Taj Pharmaceuticals is committed to ensuring the highest standards of quality, safety, and efficacy in the pharmaceutical products we manufacture and distribute. We recognize that our products impact the health and well-being of patients worldwide, and we are dedicated to maintaining the trust of healthcare professionals and patients through our commitment to quality.

Policy Statement:

At Taj Pharmaceuticals, our Quality Assurance (QA) Policy is centered on the following key principles:

Compliance: We are committed to complying with all relevant national and international regulations and standards governing the pharmaceutical industry. Our products adhere to Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), and other applicable guidelines.

Quality Control: We implement stringent quality control processes at every stage of our product lifecycle, from research and development to manufacturing and distribution. Our goal is to consistently deliver pharmaceutical products that meet or exceed established quality specifications.

Continuous Improvement: We foster a culture of continuous improvement by regularly reviewing and enhancing our processes, systems, and technologies. This ensures that our products remain at the forefront of pharmaceutical innovation and meet evolving customer needs.

Training and Development: We invest in the development and training of our employees to ensure they have the knowledge and skills needed to maintain the highest levels of quality. We encourage a commitment to quality at all levels of the organization.

Risk Management: We identify, assess, and manage risks that may impact product quality, patient safety, or regulatory compliance. This proactive approach allows us to mitigate potential issues and maintain the integrity of our products.

Customer Focus: We prioritize the needs and expectations of our customers, including healthcare professionals and patients. We listen to their feedback, respond to their concerns, and work to continuously improve our products and services.


Top Management: The leadership team at Taj Pharmaceuticals is responsible for setting the strategic direction of the company and ensuring that quality is a fundamental part of our corporate culture.

Quality Assurance Department: The QA department is responsible for developing and implementing quality management systems, conducting audits, and ensuring compliance with regulations and standards.

Production and R&D Teams: These teams are responsible for adhering to established quality standards, processes, and procedures in the development and manufacturing of pharmaceutical products.

Employees: All employees are expected to take ownership of quality in their respective roles and contribute to the overall culture of quality at Taj Pharmaceuticals.


This Quality Assurance Policy is communicated to all employees, suppliers, and stakeholders to ensure a shared understanding of our commitment to quality. We encourage open communication and reporting of quality-related concerns and incidents.

Review and Revision:

This Quality Assurance Policy is subject to periodic review and revision to ensure its continued effectiveness and alignment with industry best practices and regulatory requirements.


At Taj Pharmaceuticals, quality is not just a commitment; it’s a way of life. We strive for excellence in all that we do, and our Quality Assurance Policy reflects our unwavering dedication to delivering safe, effective, and high-quality pharmaceutical products to improve the health and well-being of people worldwide.

For and on behalf of the Manufacturer or Producer.

In the capacity of Mr.Abhishek Singh, CEO and duly authorize to sign this Authorization on behalf of TAJ PHARMACEUTICALS LTD.

Managing quality risks involves a systematic approach:

  1. Risk Identification: Identify potential risks to product quality, including process deviations, supplier issues, and regulatory changes.
  2. Risk Assessment: Evaluate the impact and likelihood of each identified risk. Prioritize risks based on severity.
  3. Risk Mitigation: Develop strategies to mitigate or prevent identified risks. This may involve process improvements, supplier audits, or contingency plans.
  4. Monitoring: Continuously monitor processes and external factors for emerging risks. Implement proactive measures to address them.
  5. Documentation: Maintain thorough records of risk assessments, mitigation plans, and actions taken. Ensure transparency and accountability.
  6. Training: Educate employees on quality risks and their roles in risk management. Encourage a culture of vigilance and reporting.
  7. Audit and Review: Regularly audit processes to ensure compliance with risk mitigation strategies. Review and update risk assessments as needed.
  8. Communication: Maintain open lines of communication with stakeholders, including regulators and customers, to address concerns and share risk-related information.
  9. Contingency Planning: Develop contingency plans for high-impact risks to minimize disruptions and maintain product quality.
  10. Continuous Improvement: Continuously refine risk management processes based on lessons learned and changing circumstances.

By following these steps, organizations can proactively identify, assess, and mitigate quality risks, ensuring the consistent delivery of high-quality products and services.

Risk Assessment

Risk assessment is a systematic process that involves identifying, analyzing, and evaluating potential risks that can impact an organization’s objectives, operations, or projects. It is a crucial component of risk management and is used to make informed decisions about how to mitigate or manage these risks effectively. Here are the key elements of risk assessment:

1. Risk Identification: This is the first step in the process. It involves identifying and documenting all possible risks that could affect the organization. Risks can come from various sources, including internal processes, external factors, strategic decisions, and more.

2. Risk Analysis: Once risks are identified, they need to be analyzed in terms of their potential impact and likelihood of occurrence. This step helps prioritize risks by determining which ones are most significant or urgent.

  • Impact Assessment: Assess the potential consequences or impact of each risk. This could include financial losses, operational disruptions, damage to reputation, regulatory penalties, etc.
  • Likelihood Assessment: Evaluate how likely it is that each risk will occur. This assessment can be based on historical data, expert judgment, or statistical analysis.

3. Risk Evaluation: After analyzing risks, they are evaluated to determine their overall risk level. This is often done by combining the impact and likelihood assessments. Risks are typically categorized as low, medium, or high risk.

4. Risk Prioritization: Based on the evaluation, risks are prioritized. High-risk issues are given immediate attention, while low-risk issues may be monitored or addressed later.

5. Risk Mitigation Planning: For high and medium-risk issues, mitigation strategies are developed. These strategies outline specific actions to reduce the likelihood or impact of the risk. They may include process improvements, contingency plans, insurance coverage, or other risk reduction measures.

6. Risk Monitoring and Review: After mitigation measures are in place, ongoing monitoring and review are essential. This ensures that the risk landscape is continuously assessed, and adjustments are made as needed. New risks may emerge, and the effectiveness of existing mitigation measures should be evaluated.

7. Reporting: Regular reporting on the status of risk assessments and mitigation efforts is crucial. This keeps stakeholders informed and allows for timely decision-making.

8. Documentation: All aspects of the risk assessment process should be thoroughly documented. This includes the identification of risks, assessments, mitigation plans, and monitoring activities. Proper documentation is essential for accountability and future reference.

Effective risk assessment is a dynamic and iterative process that helps organizations proactively identify and manage risks to achieve their objectives while minimizing potential negative impacts. It is a fundamental component of strategic planning and operational excellence.

Risk Mitigation

Risk: Supplier Reliability Risk

Description: The primary supplier of a critical raw material for our pharmaceutical product has a history of occasional delivery delays.

Mitigation Strategy:

  1. Diversification: Identify alternative suppliers for the same raw material. Establish relationships and assess their reliability.
  2. Safety Stock: Maintain a safety stock of the raw material to cover potential delays.
  3. Contractual Agreements: Negotiate clear delivery timelines and penalties for delays with the primary supplier to incentivize on-time deliveries.
  4. Supplier Audits: Conduct regular audits of the primary supplier’s facilities to ensure compliance with quality standards and assess their commitment to improving reliability.
  5. Communication: Maintain open and transparent communication with the primary supplier, sharing our expectations and concerns regarding delivery reliability.
  6. Contingency Plan: Develop a contingency plan to address unexpected delays, including alternative sourcing options and expedited shipping arrangements.

The Four Pillars of Quality Assurance

To ensure that their coating formulations are both innovative and robust, Taj Pharma has adopted four quality by design (QbD) principles that support their Full Automated coatings. These principles are instrumental in maintaining consistent color and reliable coating performance across all batches.

1. Design of Experiment (DoE)

This process optimization technique enhances coating formulations by conducting comprehensive experiments. From development to launch, all Full Automated systems undergo rigorous assessment to ensure optimum functionality.

2. Process Validation

Taj Pharma leaves no room for compromise in ensuring that every new Full Automated system meets the required quality specifications. This validation process is conducted at every scale of manufacture across their seven interchangeable manufacturing plants worldwide.

3. Stability Testing

Following the guidelines of the International Conference on Harmonization (ICH), Taj Pharma conducts stability testing to guarantee the consistent and stable appearance, color, dispersion properties, and coating performance throughout the specified shelf-life of the product.

4. Master Formulation

A unique master formulation serves as a global reference for creating all subsequent batch records, regardless of where they are produced worldwide. This standardization is pivotal in maintaining consistent quality.